165 related articles for article (PubMed ID: 19820921)
1. Uptake of anthracyclines in vitro and in vivo in acute myeloid leukemia cells in relation to apoptosis and clinical response.
Bogason A; Bhuiyan H; Masquelier M; Paul C; Gruber A; Vitols S
Eur J Clin Pharmacol; 2009 Dec; 65(12):1179-86. PubMed ID: 19820921
[TBL] [Abstract][Full Text] [Related]
2. Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.
Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
Br J Clin Pharmacol; 2011 Apr; 71(4):514-21. PubMed ID: 21204910
[TBL] [Abstract][Full Text] [Related]
3. Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment.
Belaud-Rotureau MA; Durrieu F; Labroille G; Lacombe F; Fitoussi O; Agape P; Marit G; Reiffers J; Belloc F
Leukemia; 2000 Jul; 14(7):1266-75. PubMed ID: 10914552
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
[TBL] [Abstract][Full Text] [Related]
5. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
6. The influence of intracellular idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia.
Styczyński J; Wysocki M; Debski R; Kurylak A; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk J; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
Acta Biochim Pol; 2002; 49(1):99-107. PubMed ID: 12136962
[TBL] [Abstract][Full Text] [Related]
7. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
8. In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
Biscardi M; Caporale R; Pagliai G; Leoni F; Bernabei P; Santini V; Ciolli S; Grossi A
Leuk Res; 2003 Dec; 27(12):1125-34. PubMed ID: 12921951
[TBL] [Abstract][Full Text] [Related]
9. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179
[TBL] [Abstract][Full Text] [Related]
10. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells.
Berman E; McBride M
Blood; 1992 Jun; 79(12):3267-73. PubMed ID: 1596567
[TBL] [Abstract][Full Text] [Related]
11. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
[TBL] [Abstract][Full Text] [Related]
12. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia.
Li X; Xu S; Tan Y; Chen J
Cochrane Database Syst Rev; 2015 Jun; (6):CD010432. PubMed ID: 26037486
[TBL] [Abstract][Full Text] [Related]
13. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
Bogason A; Masquelier M; Lafolie P; Skogastierna C; Paul C; Gruber A; Vitols S
Drug Metab Lett; 2010 Dec; 4(4):228-32. PubMed ID: 20670211
[TBL] [Abstract][Full Text] [Related]
14. Comparison of uptake mechanisms for anthracyclines in human leukemic cells.
Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
Curr Drug Deliv; 2013 Aug; 10(4):404-12. PubMed ID: 23062181
[TBL] [Abstract][Full Text] [Related]
15. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004.
Creutzig U; Zimmermann M; Bourquin JP; Dworzak MN; Fleischhack G; Graf N; Klingebiel T; Kremens B; Lehrnbecher T; von Neuhoff C; Ritter J; Sander A; Schrauder A; von Stackelberg A; Starý J; Reinhardt D
Blood; 2013 Jul; 122(1):37-43. PubMed ID: 23704089
[TBL] [Abstract][Full Text] [Related]
18. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
[TBL] [Abstract][Full Text] [Related]
19. The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation.
Byun JM; Lee JO; Suh KJ; Lee J; Shin DY; Koh Y; Hong J; Bang SM; Kim I; Yoon SS
Anticancer Res; 2020 Jan; 40(1):357-366. PubMed ID: 31892587
[TBL] [Abstract][Full Text] [Related]
20. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Tidefelt U; Liliemark J; Gruber A; Liliemark E; Sundman-Engberg B; Juliusson G; Stenke L; Elmhorn-Rosenborg A; Möllgård L; Lehman S; Xu D; Covelli A; Gustavsson B; Paul C
J Clin Oncol; 2000 May; 18(9):1837-44. PubMed ID: 10784624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
